Abstract 138P
Background
Systemic inflammatory markers (SIM) are closely related to the prognosis of various tumors. However, most of the studies were mainly limited to examining the preoperative level of these markers to evaluate prognosis. Reports on the significance of postoperative SIM in predicting the long-term prognosis of gastric cancer (GC) were rare. Therefore, this study aims to explore the preoperative and postoperative longitudinal changes of SIM in patients with GC and the impact on long-term prognosis.
Methods
The prospectively collected data from 2180 patients with GC who underwent radical gastrectomy between January 2009 and December 2014 at Fujian Medical University Union Hospital (FMUUH) were retrospectively analyzed. Changes in SIM between preoperatively and 1-6 months and 12 months postoperatively were reported. Cox univariate and multivariate analyses were performed to determine the prognosis of GC.
Results
In multivariate analysis, higher preoperative systemic inflammation score (pre-SIS) was independent predictor of poor prognosis (P <0.05). Further analysis showed that the area under the curve (AUC) of pre-SIS for prediction of 5-year overall survival (OS) was highest [0.605 (95% CI 0.584-0.6250)]. The optimal time of remeasurement was 12 months postoperatively, based on a longitudinal profile of SIS and accuracy in predicting 5-year OS [AUC: 0.712 (95% CI 0.630 - 0.785)]. According to the association between the conversion of SIS and OS, we classified patients into three risk groups. Kaplan-Meier (K-M) curves showed significant differences in OS among risk groups. Further Cox multivariate regression analysis showed that only risk groups of SIS and pTNM stage were independent prognostic factors for OS.
Conclusions
The efficacy of SIS in predicting prognosis 12 months after surgery is superior, and the elevation of SIS 12 months after surgery predicts poor prognosis. These findings provide support for the remeasurement of SIS 12 months after surgery.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Scientific and Technological Innovation Joint Capital Projects of Fujian Province.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
339P - Diclofenac versus tramadol for mucositis related pain in head and neck cancer patients undergoing concurrent chemoradiation: A phase III study
Presenter: Vikas Talreja
Session: e-Poster Display Session
340P - Omega-3 fatty acids for cancer cachexia in advanced non-small cell lung cancer: A meta-analysis
Presenter: Alfredo Chua
Session: e-Poster Display Session
341P - Relationship between muscle mass and quality of life in breast cancer patients who underwent chemotherapy
Presenter: Andree Kurniawan
Session: e-Poster Display Session
342P - Comparison of 0.25 mg versus 0.75 mg of palonosetron in combination with aprepitant and dexamethasone for prevention of chemotherapy-induced nausea and vomiting following cisplatin-containing chemotherapy in patients with esophageal cancer
Presenter: Satoshi Horasawa
Session: e-Poster Display Session
343P - Head-to-head comparison of palonosetron versus granisetron for prevention of chemotherapy induced nausea and vomiting: Systematic review and meta-analysis
Presenter: Chin-Hung Hsu
Session: e-Poster Display Session
344P - Single-centre analysis of anti-resorptive agent-related osteonecrosis of the jaw in lung cancer patients
Presenter: Kohei Fujita
Session: e-Poster Display Session
345P - Thromboembolic events in brain tumour patients on bevacizumab
Presenter: Gunjesh Singh
Session: e-Poster Display Session
346P - Occurence and risk factors of chemotherapy-induced neutropenia in patients with breast cancer: A hospital-based assessment in Indonesia
Presenter: Susanna Hutajulu
Session: e-Poster Display Session
347P - Histamine blockade with loratadine for prevention of granulocyte-colony stimulating factor (G-CSF)-associated bone pain: A meta-analysis
Presenter: Mel Valerie Ordinario
Session: e-Poster Display Session
348P - Anti-VEGF inhibitors and renal safety in onco-nephrology consortium: Urinary protein/creatinine ratio (VERSiON UP study)
Presenter: Michio Nakamura
Session: e-Poster Display Session